NTLA-2002
Sponsors
Intellia Therapeutics Inc., Intellia Therapeutics
Conditions
Hereditary Angioedemahereditary angioedema due to C1 esterase inhibitor deficiency (Type 1 or 2)
Phase 1
Long-Term Follow-Up of Subjects Treated With NTLA-2002
RecruitingCTIS2023-507956-56-00
Start: 2024-05-17Target: 19Updated: 2025-12-09
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
Active, not recruitingCTIS2024-512317-40-00
Start: 2022-04-13Target: 15Updated: 2024-11-22
Phase 3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Active, not recruitingNCT06634420
Start: 2025-01-15End: 2027-09-01Updated: 2026-07-29
HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Active, not recruitingCTIS2024-515741-42-00
Start: 2025-03-28Target: 29Updated: 2025-07-11